Conformity analysis of target-volume definition for margin-directed boost in pancreatic cancer SBRT

Conformity analysis of target-volume definition for margin-directed boost in pancreatic cancer SBRT

Dettagli Bibliografici
Autori principali:	Holyoake, D, Robinson, M, Grose, D, McIntosh, D, Sebag-Montefiore, D, Radhakrishna, G, Patel, N, Mukherjee, S, Hawkins, M
Natura:	Conference item
Pubblicazione:	Elsevier 2016

Documenti analoghi

Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer.
di: Holyoake, D, et al.
Pubblicazione: (2016)

Analysis of on-trial quality assurance for the SPARC clinical trial using novel peer-review methodology
di: Holyoake, D, et al.
Pubblicazione: (2018)

A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol.
di: Holyoake, D, et al.
Pubblicazione: (2016)

SPARC: A phase-I trial of pre-operative margin-intensified stereotactic radiotherapy for pancreatic cancer at high risk of positive resection margins
di: Holyoake, D, et al.
Pubblicazione: (2018)

EP-1720: Impact of contouring variability on tumour control and normal tissue toxicity in liver SBRT
di: Robinson, M, et al.
Pubblicazione: (2016)

Permit to enter no-fly-zone: risk-adapted mediastinal SBRT for oligometastases safe and effective
di: Holyoake, D, et al.
Pubblicazione: (2017)

Stomach dose-volume parameters and clinical factors predict acute toxicity in pancreatic cancer chemoradiotherapy
di: Holyoake, D, et al.
Pubblicazione: (2017)

EP-1941: Assessment of variation in planning benchmark case for ABC-07 trial of liver SBRT
di: Eaton, D, et al.
Pubblicazione: (2016)

Dosimetric parameters predict toxicity in chemoradiotherapy with nelfinavir for pancreatic cancer
di: Holyoake, D, et al.
Pubblicazione: (2016)

Early stage anal margin cancer: towards evidence‐based management
di: Renehan, A, et al.
Pubblicazione: (2019)

Investigating the toxicity and safety of radiotherapy for pancreatic cancer
di: Holyoake, D
Pubblicazione: (2018)

Dosimetric comparison of multiple SBRT delivery platforms for pancreatic cancer
di: Yongchun Song, et al.
Pubblicazione: (2024-11-01)

Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: the phase 1/randomised phase 2 SCALOP-2 trial
di: Mukherjee, S, et al.
Pubblicazione: (2024)

Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2)
di: Strauss, V, et al.
Pubblicazione: (2019)

Stomach dose-volume predicts acute gastrointestinal toxicity in chemoradiotherapy for locally advanced pancreatic cancer
di: Holyoake, DLP, et al.
Pubblicazione: (2018)

Modelling duodenum radiotherapy toxicity using cohort dose-volume-histogram data
di: Holyoake, D, et al.
Pubblicazione: (2017)

Early outcomes of MR-guided SBRT for patients with recurrent pancreatic adenocarcinoma
di: Spencer J. Poiset, et al.
Pubblicazione: (2024-05-01)

SCALOP-2: A multi-centre randomised trial of induction chemotherapy followed by capecitabine +/-nelfinavir with high or standard dose radiotherapy for locally advanced pancreatic cancer (LAPC): Results of stage 1 - the non-randomised dose-finding component
di: Mukherjee, S, et al.
Pubblicazione: (2018)

Clinical experience with adaptive MRI-guided pancreatic SBRT and the use of abdominal compression to reduce treatment volume
di: William S. Ferris, et al.
Pubblicazione: (2024-08-01)

Four-dimensional computed tomography contouring variability in stereotactic body radiotherapy of non-resectable biliary tract cancer
di: Robinson, M, et al.
Pubblicazione: (2017)

SCALOP-2: A randomised trial of induction GEMABX followed by chemoradiation (high/standard dose radiation) +/-nelfinavir for locally advanced pancreatic cancer: results of the dose-finding component
di: Mukherjee, S, et al.
Pubblicazione: (2018)

Meta-analysis of toxicity and small-bowel radiotherapy dose-volume: “omnibus consequentia”
di: Holyoake, D, et al.
Pubblicazione: (2018)

Improving radiotherapy quality assurance in clinical trials: assessment of target volume delineation of the pre-accrual benchmark case.
di: Gwynne, S, et al.
Pubblicazione: (2013)

Systematic review and meta-analysis of small bowel dose–volume and acute toxicity in conventionally-fractionated rectal cancer radiotherapy
di: Holyoake, D, et al.
Pubblicazione: (2019)

Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer—A Critical Review and Practical Consideration
di: Petr Burkoň, et al.
Pubblicazione: (2022-10-01)

SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer
di: Virdee, P, et al.
Pubblicazione: (2017)

Personalized dose escalation in anal cancer
di: Robinson, M, et al.
Pubblicazione: (2016)

Modulation of myocardial creatine transporter levels and the effects of gene regulation and post-translational modification on its function
di: Sebag-Montefiore, L
Pubblicazione: (2012)

P-233: SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer
di: Virdee, P, et al.
Pubblicazione: (2017)

Sharing Mono-Institutional Experience of Treating Pancreatic Cancer with Stereotactic Body Radiation Therapy (SBRT)
di: Asmara Waheed, et al.
Pubblicazione: (2024-10-01)

Impact of Using Unedited CT-Based DIR-Propagated Autocontours on Online ART for Pancreatic SBRT
di: Alba Magallon-Baro, et al.
Pubblicazione: (2022-06-01)

Pelvic re-irradiation using stereotactic ablative radiotherapy (SABR): A systematic review.
di: Murray, L, et al.
Pubblicazione: (2017)

Conformational change in an MFS protein: MD simulations of LacY.
di: Holyoake, J, et al.
Pubblicazione: (2007)

Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2)
di: Victoria Y. Strauss, et al.
Pubblicazione: (2019-02-01)

Integrating IL-12 mRNA nanotechnology with SBRT eliminates T cell exhaustion in preclinical models of pancreatic cancer
di: Angela L. Hughson, et al.
Pubblicazione: (2024-12-01)

Retrieval practice, with or without mind mapping, boosts fact learning in primary school children.
di: Stuart J Ritchie, et al.
Pubblicazione: (2013-01-01)

Treatment planning of dose escalation for anal cancer in the PLATO trial
di: Abbott, N, et al.
Pubblicazione: (2017)

Boost modalities in cervical cancer: dosimetric comparison between intracavitary BT vs. intracavitary + interstitial BT vs. SBRT.
di: Sofian Benkhaled, et al.
Pubblicazione: (2023-06-01)

Prognostic factors for patients with anal cancer treated with conformal radiotherapy—a systematic review
di: Stelios Theophanous, et al.
Pubblicazione: (2022-06-01)

Conformal Carroll scalars with boosts
di: Stefano Baiguera, Gerben Oling, Watse Sybesma, Benjamin T. Søgaard
Pubblicazione: (2023-04-01)